349 related articles for article (PubMed ID: 28917384)
1. Serious infections among a large cohort of subjects with systemically treated psoriasis.
Dobry AS; Quesenberry CP; Ray GT; Geier JL; Asgari MM
J Am Acad Dermatol; 2017 Nov; 77(5):838-844. PubMed ID: 28917384
[TBL] [Abstract][Full Text] [Related]
2. Malignancy rates in a large cohort of patients with systemically treated psoriasis in a managed care population.
Asgari MM; Ray GT; Geier JL; Quesenberry CP
J Am Acad Dermatol; 2017 Apr; 76(4):632-638. PubMed ID: 28162854
[TBL] [Abstract][Full Text] [Related]
3. Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
Kalb RE; Fiorentino DF; Lebwohl MG; Toole J; Poulin Y; Cohen AD; Goyal K; Fakharzadeh S; Calabro S; Chevrier M; Langholff W; You Y; Leonardi CL
JAMA Dermatol; 2015 Sep; 151(9):961-9. PubMed ID: 25970800
[TBL] [Abstract][Full Text] [Related]
4. Risk of adverse events in psoriasis patients receiving classic systemic drugs and biologics in a 5-year observational study of clinical practice: 2008-2013 results of the Biobadaderm registry.
Carretero G; Ferrandiz C; Dauden E; Vanaclocha Sebastián F; Gómez-García FJ; Herrera-Ceballos E; De la Cueva-Dobao P; Belinchón I; Sánchez-Carazo JL; Alsina-Gibert M; López-Estebaranz JL; Ferrán M; Torrado R; Carrascosa JM; Carazo C; Rivera R; Jiménez-Puya R; García-Doval I;
J Eur Acad Dermatol Venereol; 2015 Jan; 29(1):156-63. PubMed ID: 24684267
[TBL] [Abstract][Full Text] [Related]
5. Adverse events resulting in withdrawal of biologic therapy for psoriasis in real-world clinical practice: A Canadian multicenter retrospective study.
Kim WB; Marinas JE; Qiang J; Shahbaz A; Greaves S; Yeung J
J Am Acad Dermatol; 2015 Aug; 73(2):237-41. PubMed ID: 26026334
[TBL] [Abstract][Full Text] [Related]
6. Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: patients ineligible vs eligible for randomized controlled trials.
Garcia-Doval I; Carretero G; Vanaclocha F; Ferrandiz C; Daudén E; Sánchez-Carazo JL; Alsina M; Herrera-Ceballos E; Gómez-García FJ; Ferrán M; López-Estebaranz JL; Hernanz JM; Belinchón-Romero I; Vilar-Alejo J; Rivera R; Carrascosa JM; Carazo C
Arch Dermatol; 2012 Apr; 148(4):463-70. PubMed ID: 22508869
[TBL] [Abstract][Full Text] [Related]
7. Serious infection risk in children with psoriasis on systemic treatment: A propensity score-matched population-based study.
Schneeweiss MC; Huang JT; Wyss R; Schneeweiss S; Merola JF
J Am Acad Dermatol; 2020 Jun; 82(6):1337-1345. PubMed ID: 32142748
[TBL] [Abstract][Full Text] [Related]
8. Risk of Subsequent Infection Among Patients Receiving Tumor Necrosis Factor Inhibitors and Other Disease-Modifying Antirheumatic Drugs.
Accortt NA; Bonafede MM; Collier DH; Iles J; Curtis JR
Arthritis Rheumatol; 2016 Jan; 68(1):67-76. PubMed ID: 26359948
[TBL] [Abstract][Full Text] [Related]
9. Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritis.
Li X; Andersen KM; Chang HY; Curtis JR; Alexander GC
Ann Rheum Dis; 2020 Feb; 79(2):285-291. PubMed ID: 31672774
[TBL] [Abstract][Full Text] [Related]
10. Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR).
Yiu ZZN; Ashcroft DM; Evans I; McElhone K; Lunt M; Smith CH; Walton S; Murphy R; Reynolds NJ; Ormerod AD; Griffiths CEM; Warren RB;
Br J Dermatol; 2019 Feb; 180(2):329-337. PubMed ID: 30070708
[TBL] [Abstract][Full Text] [Related]
11. Biologic and Conventional Systemic Therapies Show Similar Safety and Efficacy in Elderly and Adult Patients With Moderate to Severe Psoriasis.
Garber C; Plotnikova N; Au SC; Sorensen EP; Gottlieb A
J Drugs Dermatol; 2015 Aug; 14(8):846-52. PubMed ID: 26267729
[TBL] [Abstract][Full Text] [Related]
12. Increased risk of arrhythmia in patients with psoriatic disease: A nationwide population-based matched cohort study.
Chiu HY; Chang WL; Huang WF; Wen YW; Tsai YW; Tsai TF
J Am Acad Dermatol; 2015 Sep; 73(3):429-38. PubMed ID: 26188627
[TBL] [Abstract][Full Text] [Related]
13. Systemic Therapy for Psoriasis and the Risk of Herpes Zoster: A 500,000 Person-year Study.
Shalom G; Zisman D; Bitterman H; Harman-Boehm I; Greenberg-Dotan S; Dreiher J; Feldhamer I; Moser H; Hammerman A; Cohen Y; Cohen AD
JAMA Dermatol; 2015 May; 151(5):533-8. PubMed ID: 25797026
[TBL] [Abstract][Full Text] [Related]
14. Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases.
Grijalva CG; Chen L; Delzell E; Baddley JW; Beukelman T; Winthrop KL; Griffin MR; Herrinton LJ; Liu L; Ouellet-Hellstrom R; Patkar NM; Solomon DH; Lewis JD; Xie F; Saag KG; Curtis JR
JAMA; 2011 Dec; 306(21):2331-9. PubMed ID: 22056398
[TBL] [Abstract][Full Text] [Related]
15. Safety of classic and biologic systemic therapies for the treatment of psoriasis in elderly: an observational study from national BIOBADADERM registry.
Medina C; Carretero G; Ferrandiz C; Dauden E; Vanaclocha F; Gómez-García FJ; Herrera-Ceballos E; De la Cueva-Dobao P; Belinchón I; Sánchez-Carazo JL; Alsina M; López-Estebaranz JL; Ferrán M; Carrascosa JM; Torrado R; Argila D; Rivera R; Jiménez-Puya R; García-Doval I;
J Eur Acad Dermatol Venereol; 2015 May; 29(5):858-64. PubMed ID: 25185962
[TBL] [Abstract][Full Text] [Related]
16. A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and real-world populations in psoriasis.
Yiu ZZN; Mason KJ; Barker JNWN; Hampton PJ; McElhone K; Smith CH; Warren RB; Griffiths CEM; Lunt M; Burden AD;
Br J Dermatol; 2019 Dec; 181(6):1265-1271. PubMed ID: 30822358
[TBL] [Abstract][Full Text] [Related]
17. Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR).
Strober B; Gooderham M; de Jong EMGJ; Kimball AB; Langley RG; Lakdawala N; Goyal K; Lawson F; Langholff W; Hopkins L; Fakharzadeh S; Srivastava B; Menter A
J Am Acad Dermatol; 2018 Jan; 78(1):70-80. PubMed ID: 29102053
[TBL] [Abstract][Full Text] [Related]
18. Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): experience with infliximab and other systemic and biologic therapies.
Gottlieb AB; Kalb RE; Langley RG; Krueger GG; de Jong EM; Guenther L; Goyal K; Fakharzadeh S; Chevrier M; Calabro S; Langholff W; Menter A
J Drugs Dermatol; 2014 Dec; 13(12):1441-8. PubMed ID: 25607786
[TBL] [Abstract][Full Text] [Related]
19. Adverse Medical Conditions Across Treatment Options in Patients With Psoriasis: A Claims-Based Analysis.
Wu JJ; Armstrong A; Singh R; Cloutier M; Gauthier-Loiselle M; Gagnon-Sanschagrin P; Arikan D; Fleischer A; Guérin A; Ganguli A
J Drugs Dermatol; 2018 Nov; 17(11):1211-1218. PubMed ID: 30500143
[TBL] [Abstract][Full Text] [Related]
20. Comparative Effectiveness and Safety of Anti-Tumor Necrosis Factor Agents in Biologic-Naive Patients With Crohn's Disease.
Singh S; Heien HC; Sangaralingham LR; Schilz SR; Kappelman MD; Shah ND; Loftus EV
Clin Gastroenterol Hepatol; 2016 Aug; 14(8):1120-1129.e6. PubMed ID: 27058635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
